November 2019

There was quite a stir in the healthcare industry – and to our clients – when HHS released a proposed rule aimed at eliminating rebates from pharmaceutical companies to PBMs in Medicare Part D and in Medicaid managed care organizations. Will manufacturers unilaterally lower the list prices? What’s the impact on premiums? More>>